Industry Trend

Site Sections


Menu













© 2023. All Rights reserved.

Overview for ASTRAZENECA

All Data per March 3, 2023

Industry:

Drug Manufacturers—General

Last Close:

107.84 GBP

Expected Dividend:

2.74 %

Payoffs per Year:

2.0
Business Summary

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.


Competitors View

Ordering

ABBVIE

USA
1.03 4.28%
3.61%
7.39% 5.46% 1.0 4.36
-9.47%
43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN
0.96 2.56%
0.0%
22.5% 6.68% 1.0 4.24
-32.13%
32.9 15.38% 77.21 2.0

PFIZER

USA
0.95 3.64%
3.96%
2.76% 3.76% 1.0 3.02
-11.11%
49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR
1.04 4.07%
2.74%
1.15% 3.92% 1.0 11.56
-3.86%
98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN
1.05 4.24%
0.0%
0.0% 3.88% 1.0 8.15
-17.26%
35.15 18.52% 61.0 5.0

SANOFI

FRA
1.01 3.78%
4.03%
0.74% 3.58% 1.0 0.57
-12.18%
51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA
0.98 2.8%
3.1%
1.83% 2.78% 1.0 0.5
-24.44%
34.92 17.8% 32.88 7.0

MERCK & CO.

USA
1.12 3.12%
2.64%
2.24% 3.15% 1.0 2.31
-11.68%
55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN
0.96 1.88%
1.67%
7.74% 2.44% 1.0 3.6
-15.61%
35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA
1.16 2.74%
3.6%
5.91% 3.26% 1.0 0.15
-42.43%
33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA
1.04 2.43%
1.22%
2.86% 2.52% 1.0 7.52
-12.71%
42.91 5.87% 18.4 11.0

ROCHE

CHE
0.92 3.28%
3.51%
0.79% 3.11% 1.0 1.4
-15.85%
37.23 2.14% 26.53 12.0

AMGEN

USA
1.0 2.42%
3.28%
8.46% 3.24% 1.0 3.5
-9.93%
35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR
0.96 5.37%
5.27%
0.35% 5.0% -0.5 0.21
-24.56%
49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN
0.96 2.43%
0.0%
1.74% 2.4% 1.0 1.09
-19.06%
27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN
0.93 2.21%
2.54%
0.0% 2.02% 1.0 -0.41
-14.62%
28.52 12.2% 71.29 16.0

BAYER

GER
1.02 2.51%
3.99%
4.7% 2.83% 0.5 -0.36
-58.76%
36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA
0.98 2.68%
0.0%
0.0% 2.46% 1.0 -1.0
13.03%
44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP
0.98 1.5%
nan%
4.84% 1.7% -0.5 0.24
-46.29%
31.86 -1.95% 31.7 nan


Information for ASTRAZENECA

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2012 29.10 1.82 6.25
2013 35.74 1.80 5.04
2014 45.56 1.70 3.73
2015 46.16 1.82 3.94
2016 44.38 2.00 4.51
2017 51.21 2.19 4.28
2018 58.73 2.02 3.44
2019 76.07 2.19 2.88
2020 73.24 2.16 2.95
2021 86.78 2.02 2.33
2023 107.84 2.95 2.74

Fundamentals

Chart